How the Diabetic Supply Buyback Market Is Solving a $5 Billion Healthcare Waste Problem

Healthcare and Supply Chain Management

The U.S. healthcare system produces a significant surplus of unused, sealed diabetic supplies annually. These surpluses arise from insurance auto-refill programs, medication transitions, and the widespread adoption of GLP-1 therapies, leading to a structural surplus that pharmacies cannot accept, and regulators have no framework to manage.

Diabetic supply buyback platforms have emerged to connect this surplus with the 38.4 million Americans managing diabetes on limited budgets.

The Structural Problem: Accumulation of Unused Diabetic Supplies

The surplus of diabetic supplies is due to systemic design issues in insurance, prescriptions, and medication transitions.

Auto-Refill Programs and Consumption Discrepancies

Insurance plans often mandate 90-day auto-refill cycles for chronic condition supplies. These cycles operate on fixed schedules, independent of patient consumption. Changes such as reduced testing frequency or the switch to a continuous glucose monitor contribute to surplus. Pharmacies cannot legally accept returns on dispensed products, leading to excess inventory.

Impact of GLP-1 Transition on Insulin Surplus

From 2022 to 2025, GLP-1 receptor agonists such as Ozempic, Mounjaro, Wegovy, and Trulicity were rapidly adopted, shifting millions of Type 2 diabetes patients away from traditional insulin therapy. This has resulted in a significant surplus of unused insulin pens, test strips, and pen needles.

After a patient's death or transition to long-term care, families often find large quantities of accumulated diabetic supplies. These items, already paid for by insurance, are frequently discarded due to lack of return options.

The Demand Side: Diabetes Affordability Challenges

The surplus of supplies exists alongside a significant affordability issue for millions of Americans with diabetes.

Cost of Insulin and Testing Supplies Without Insurance

The American Diabetes Association (ADA) estimates U.S. diabetes-related healthcare costs at $412 billion annually. Research by Yale School of Medicine indicates insulin prices have increased by over 300% in two decades. Retail prices for a single box of brand-name test strips range from $30 to $150. One in four insulin users reports rationing doses due to cost.

Policy Improvements and Their Limitations

The Inflation Reduction Act capped Medicare insulin copays at $35 per month starting in 2023, with Medicare-negotiated drug prices effective in 2026. These measures benefit seniors but leave approximately 22 million working-age adults with diabetes vulnerable to high out-of-pocket costs.

Buyback Platforms: Bridging the Surplus-to-Need Gap

Diabetic supply buyback services facilitate a secondary market connecting surplus holders with buyers seeking cost-effective supplies.

The buyback process involves sellers submitting product details, after which the company provides a prepaid shipping label. Upon receipt and verification of the supplies, the company issues payment via PayPal or check within 1 to 2 business days.

The most common products in the buyback market include sealed diabetic test strips, Dexcom G6 and G7 sensors, FreeStyle Libre sensors, insulin pens (Humalog, Novolog, Lantus), pen needles, and insulin pump supplies. All products must be unexpired and in original sealed packaging.

Diabetics Trust, a buyback service, reports a 40% increase in insulin pen submissions over the past 18 months, corresponding with GLP-1 adoption rates. The company processes thousands of shipments monthly, with a significant portion originating from caregivers or family members managing surplus after medication changes.

Regulatory Landscape and Market Outlook

The diabetic supply buyback market operates under varying regulatory frameworks, depending on product type and state.

Regulations for Over-the-Counter vs. Prescription Products

Diabetic test strips, lancets, and pen needles are generally classified as over-the-counter products, simplifying resale. However, insulin and certain CGM components involve prescription-level regulatory considerations that differ by jurisdiction. Currently, no federal framework specifically governs the resale of sealed diabetic supplies held by consumers.

Need for Formalized Redistribution Infrastructure

Some states have implemented drug repository programs for redistributing unused medications, though coverage is limited and inconsistent. Organizations like the ADA advocate for expanded frameworks, especially for high-cost diabetes technology. As diabetes prevalence increases and medication transitions become more common, the buyback market is expected to grow, offering a practical solution to address both healthcare waste and patient access.

Based on reporting by TechBullion.